We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

84 hedge funds and large institutions have $297M invested in Eiger BioPharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

164% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 11

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

84% more call options, than puts

Call options by funds: $26.2M | Put options by funds: $14.2M

27% more funds holding

Funds holding: 66 → 84 (+18)

20% more capital invested

Capital invested by funds: $248M → $297M (+$49.1M)

Holders
84
Holders Change
+18
Holders Change %
+27.27%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
28
Increased
29
Reduced
11
Closed
10
Calls
$26.2M
Puts
$14.2M
Net Calls
+$12M
Net Calls Change
+$12M

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$19.4M
2
Millennium Management
Millennium Management
New York
+$16.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.43M
4
CWG
C WorldWide Group
Denmark
+$5.83M
5
Renaissance Technologies
Renaissance Technologies
New York
+$5.38M

Top Sellers

Rank Fund Capital Flow
1
TCM
Tekla Capital Management
Massachusetts
-$11.8M
2
EAM
EverPoint Asset Management
Connecticut
-$5.86M
3
PHS
PFM Health Sciences
California
-$5.64M
4
FCM
Farallon Capital Management
California
-$3.1M
5
SFM
Sphera Funds Management
Israel
-$2.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
26
Soros Fund Management
New York
$2.27M +$2.33M +267 New
CS
27
Credit Suisse
Switzerland
$2.06M +$559K +64 +36%
BIT
28
BlackRock Institutional Trust
California
$2.03M +$1.72M +197 +480%
Morgan Stanley
29
Morgan Stanley
New York
$2M +$2.05M +234 +23,400%
GTC
30
Ghost Tree Capital
New York
$1.89M +$1.16M +133 +149%
Barclays
31
Barclays
United Kingdom
$1.77M +$1.91M +219 New
Wells Fargo
32
Wells Fargo
California
$1.77M -$26.2K -3 -1%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.46M +$323K +37 +28%
Two Sigma Investments
34
Two Sigma Investments
New York
$1.38M +$979K +112 +224%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$1.11M +$87.4K +10 +8%
BCM
36
Bridgeway Capital Management
Texas
$1.06M – – –
SI
37
Shaker Investments
Ohio
$1.04M – – –
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$947K +$769K +88 +383%
BA
39
BlackRock Advisors
Delaware
$932K +$935K +107 +5,350%
OPPM
40
Opus Point Partners Management
New York
$803K – – –
TD Asset Management
41
TD Asset Management
Ontario, Canada
$790K – – –
RCM
42
RA Capital Management
Massachusetts
$775K – – –
FCM
43
Farallon Capital Management
California
$758K -$3.1M -355 -80%
TI
44
Turner Investments
Pennsylvania
$753K +$769K +88 New
Connor, Clark & Lunn Investment Management (CC&L)
45
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$676K +$481K +55 +229%
RJA
46
Raymond James & Associates
Florida
$657K +$323K +37 +93%
PVI
47
Pura Vida Investments
New York
$636K – – –
PAM
48
Panagora Asset Management
Massachusetts
$618K +$629K +72 New
DC
49
Deere & Company
Illinois
$510K +$525K +60 New
D.E. Shaw & Co
50
D.E. Shaw & Co
New York
$489K +$122K +14 +33%
1
2
3 4

EIGR Hedge Fund Activity: Q1 2015 in Review

84 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2015, worth a combined $297M — up 20% from $248M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new EIGR positions and 10 closed out — a net gain of 18 holders — while 29 added to existing stakes and 11 trimmed.

The largest buyer was Mangrove Partners, opening a new position worth an estimated $19.4M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $11.8M sold.

  • 84 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2015, up from 66 in Q4 2014.
  • Funds reported $297M of Eiger BioPharmaceuticals, Inc. stock for Q1 2015, up 20% quarter-over-quarter.
  • 28 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2015 and 10 closed out, a net change of +18 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2015 was Mangrove Partners, an estimated $19.4M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2015 was Tekla Capital Management, an estimated $11.8M sold.

Based on aggregated 13F filings for Q1 2015.